DEF: Schrödinger Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Schrödinger, Inc. will hold its 2025 annual meeting of stockholders virtually on June 18, 2025, to vote on director elections, executive compensation, and auditor ratification.

Summary

• Schrödinger, Inc. will host its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, at 12:00 p.m. Eastern time.
• Stockholders will vote on the election of four Class II directors (Jeffrey Chodakewitz, Michael Lynton, Nancy A. Thornberry, and Bridget van Kralingen) for a three-year term expiring in 2028.
• An advisory vote on executive compensation will be conducted.
• The ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, will be voted on.
• The board of directors recommends voting FOR the election of directors, FOR the approval of executive compensation, and FOR the ratification of the accounting firm appointment.
• The company plans to mail the Notice of Availability of Proxy Materials on or about April 24, 2025.
• Stockholders of record as of April 21, 2025, are entitled to vote.
• The company highlights its 2024 total revenue of $207.5 million and software revenue of $180.4 million, a 13% increase from 2023.
• The annual contract value (ACV) of the top 10 customers increased by 43% over 2023, reaching $73.1 million.
• The company entered into a multi-target research collaboration and license agreement with Novartis Pharma AG, including receipt of a $150 million upfront payment and the potential to receive up to $2.272 billion in milestone payments plus royalties.
• The company is progressing clinical trials for SGR-1505, SGR-2921 and SGR-3515.
• The company launched an initiative to expand its computational platform to predict toxicology risk early in drug discovery, which is being funded by $19.5 million in grants from the Bill & Melinda Gates Foundation.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong financial results and strategic collaborations, but also acknowledges inherent risks and uncertainties associated with forward-looking statements.

Positives

• Strong stockholder support for the executive compensation program at the 2024 annual meeting.
• Increased adoption of software by largest customers, with ACV of top 10 customers up 43% over 2023.
• Multi-target research collaboration and license agreement with Novartis Pharma AG, including a $150 million upfront payment and potential milestone payments of up to $2.272 billion.
• Progress in clinical trials for multiple drug candidates.
• Initiative to expand computational platform for toxicology risk prediction funded by $19.5 million in grants from the Bill & Melinda Gates Foundation.

Risks

• The document contains forward-looking statements that are subject to various risks and uncertainties, including demand for the software platform, reliance on third-party providers, and uncertainties inherent in drug development and commercialization.
• The relatively low level of support for the election of directors proposal last year was primarily related to the classified structure of the board and the number of other public company boards on which our directors served.

Future Outlook

The company looks forward to carrying the momentum from 2024 through 2025, focusing on expanding its computational platform and progressing its drug discovery programs.

Industry Context

The document highlights Schrödinger's position in transforming therapeutics and materials discovery through its physics-based computational platform, competing with traditional methods and other computational approaches in the biopharmaceutical and industrial sectors.

Comparison to Industry Standards

• The document references a peer group of publicly traded companies in the life sciences and software industries, including 10x Genomics, Adaptive Biotechnologies Corp., Blueprint Medicines Corp., BridgeBio Pharma, Inc., CRISPR Therapeutics AG, Denali Therapeutics Inc., Doximity, Ginkgo Bioworks Holdings, Inc., Halozyme Therapeutics, Inc., Inspire Medical Systems, Inc., Ionis Pharmaeuticals, Pacific Biosciences of California, Quanterix Corporation, Recursion Pharmaceuticals, Inc., Twist Bioscience Corp., Appian Corporation, Certara, Inc., Yext, Inc., and Zuora Inc.
• These companies are used to benchmark executive and director compensation levels.
• The selection criteria for the peer group include annual revenues of $100 million to $600 million, market capitalization of approximately one-third to three times Schrödinger's market capitalization, and headcount of one-third to three times Schrödinger's projected headcount.

Related Party Transactions

• Consulting agreement with Richard Friesner, a director, for $428,400 in 2024.
• Royalty payments to Columbia University, with a portion distributed to Richard Friesner and his laboratory.
• Agreement with Gates Ventures, LLC, controlled by William H. Gates III, for a research project, with $3,800,000 received as of the date hereof.
• Share Exchange Agreement with Bill & Melinda Gates Foundation Trust, a holder of more than 5% of our voting securities, pursuant to which the Bill & Melinda Gates Foundation Trust has the right to exchange any of their shares of common stock for limited common stock.
• Registration rights agreement with certain holders of our voting securities, including some of our 5% stockholders and their affiliates.
• Indemnification agreements with all of our directors and executive officers.

Stakeholder Impact

• Shareholders: Impacted by decisions on director elections, executive compensation, and auditor ratification.
• Employees: Affected by executive compensation policies and overall company performance.
• Customers: Benefit from the company's focus on improving its software platform and drug discovery programs.
• Suppliers: May be impacted by the company's financial performance and strategic collaborations.
• Creditors: Interested in the company's financial stability and ability to meet its obligations.

Next Steps

• Stockholders are encouraged to vote their shares prior to the Annual Meeting.
• The company will continue its stockholder outreach to seek support for annual meeting proposals and solicit feedback.
• The company will continue to focus on ESG issues and increase corporate transparency.

Key Dates

Keywords

stockholders, directors, compensation, Schrödinger, annual meeting, proxy statement, KPMG, executive, governance, equity